Pulmonary embolism (PE) is a life-threatening condition in which a blood clot travels to the lungs, lodging in the pulmonary arteries and blocking blood flow. It is a serious medical emergency that requires prompt diagnosis and treatment. The risk factors for PE include age, gender, certain medical conditions, lifestyle choices, and family history. In this comprehensive guide, we will explore the risk factors associated with PE and discuss ways to reduce your risk.
Age is one of the most significant risk factors for developing PE. The risk of PE increases with age, with the highest risk group being those over the age of 75. This is likely due to the increased likelihood of developing other medical conditions, such as deep vein thrombosis, which can lead to the formation of a blood clot that can then travel to the lungs.
Women are at a higher risk of developing PE than men. This is likely due to the fact that women tend to have higher levels of hormones, such as estrogen, which can increase the risk of blood clotting. Additionally, women are more likely to take certain medications, such as birth control pills, which can also increase the risk of developing PE.
Certain medical conditions can increase the risk of developing PE. These include cancer, heart disease, stroke, obesity, and inflammatory bowel disease. Additionally, certain medications, such as those used to treat cancer or autoimmune diseases, can also increase the risk of PE.
Certain lifestyle choices can also increase the risk of developing PE. These include smoking, being sedentary, and being immobile for extended periods of time (such as during a long plane flight). Additionally, those who are pregnant or have recently given birth are at an increased risk of developing PE.
Having a family history of PE can also increase the risk of developing the condition. This is likely due to the fact that certain genetic factors can increase the risk of clotting. Additionally, those with a family history of certain medical conditions, such as cancer or heart disease, may also be at an increased risk of developing PE.
Although some risk factors for PE cannot be changed (such as age and family history), there are steps you can take to reduce your risk. These include: • Maintaining a healthy weight. • Exercising regularly. • Not smoking. • Taking medications as prescribed. • Avoiding long periods of immobility, such as during a long plane flight. • Wearing compression stockings if you are at an increased risk of blood clots.
Pulmonary embolism is a serious medical emergency that requires prompt diagnosis and treatment. The risk factors for PE include age, gender, certain medical conditions, lifestyle choices, and family history. By understanding the risk factors associated with PE and taking steps to reduce your risk, you can help to prevent this potentially life-threatening condition.
1.
'Chemo brain' cognitive issues linked to poor lymphatic-system drainage
2.
First-Line HCC Trial's Lenvatinib-Pembrolizumab Combo Misses Target.
3.
Anti-PD-L1 Plus Targeted Agent No Better Than Chemo for Resistant NSCLC
4.
Advanced Solid Tumors May Benefit from Investigative Immunotherapy Combo.
5.
For the treatment of paroxysmal nocturnal hemoglobinuria, the FDA has approved an oral factor B inhibitor.
1.
All You Need To Know About Partial Thromboplastin Time (PTT) Test
2.
Optimizing Cancer Care: Multidisciplinary Approaches and Supportive Strategies
3.
Multimodal Data Fusion with Deep Neural Networks - Revolutionizing Oncology with Precision Cancer Diagnosis 2025
4.
Gene Signatures and Their Implications in Oncology: Decoding the Blueprint for Personalized Cancer Treatment
5.
Breakthroughs in Cancer Care: From Rare Diagnoses to Advanced and Early-Stage Treatments
1.
International Lung Cancer Congress®
2.
Future NRG Oncology Meeting
3.
Genito-Urinary Oncology Summit 2026
4.
ISMB 2026 (Intelligent Systems for Molecular Biology)
5.
Annual International Congress on the Future of Breast Cancer East
1.
First Line Combination Therapy- The Overall Survival Data in NSCLC Patients
2.
Pazopanib: A Game-Changer in Managing Advanced Renal Cell Carcinoma - Part IV
3.
Post Progression Approaches After First-line Third-Generaion ALK Inhibitors
4.
Evolving Space of First-Line Treatment for Urothelial Carcinoma- Case Discussion
5.
Revolutionizing Treatment of ALK Rearranged NSCLC with Lorlatinib - Part I
© Copyright 2026 Hidoc Dr. Inc.
Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation